ストックスクリーナーアプリを入手
47.64
57.85%
17.46
アフターアワーズ：
47.58
-0.06
-0.13%
前日終値:
$30.18
開ける：
$47.62
24時間の取引高:
22.62M
Relative Volume:
40.62
時価総額：
$1.22B
収益：
-
当期純損益:
$11.77M
株価収益率:
82.35
EPS:
0.5785
ネットキャッシュフロー:
$-19.23M
1週間 パフォーマンス:
+102.12%
1か月 パフォーマンス:
+129.92%
6か月 パフォーマンス:
+231.29%
1年 パフォーマンス:
+170.99%
1日の値動き範囲:
$47.57
$47.69
1週間の範囲:
$23.22
$47.69
52週間の値動き範囲:
$11.56
$47.69
Tourmaline Bio Inc Stock (TRML) Company Profile
TRML を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TRML
Tourmaline Bio Inc
|
47.64 | 775.39M | 0 | 11.77M | -19.23M | 0.5785 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.48 | 101.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
482.13 | 59.64B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.53 | 59.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
767.00 | 47.00B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
351.13 | 38.12B | 3.81B | -644.79M | -669.77M | -6.24 |
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-23 | 開始されました | Chardan Capital Markets | Buy |
| 2025-03-06 | 開始されました | Wedbush | Outperform |
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-11-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2023-12-15 | 開始されました | Jefferies | Buy |
| 2023-12-04 | 再開されました | H.C. Wainwright | Buy |
| 2023-11-17 | 開始されました | Truist | Buy |
| 2023-10-31 | 開始されました | Guggenheim | Buy |
| 2023-10-25 | 開始されました | Piper Sandler | Overweight |
| 2022-10-20 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
すべてを表示
Tourmaline Bio Inc (TRML) 最新ニュース
Tourmaline steers CV disease asset into $1.4B Novartis sale - BioCentury
Health Care Up on Deal Activity -- Health Care Roundup - MarketScreener
Novartis to Acquire Tourmaline Bio in $1.4 Billion Deal - ca.finance.yahoo.com
Novartis buying Tourmaline and its anti-IL-6 cardio drug for $1.4B - BioWorld MedTech
Tourmaline Bio Stocks Soar Amid Promising Results - timothysykes.com
Jefferies downgrades Tourmaline Bio stock to Hold following Novartis acquisition - Investing.com Canada
Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More Movers - Barron's
Big Gains And Big Losses Shape A Busy Day For Healthcare Stocks - Finimize
Novartis To Acquire Tourmaline Bio in $1.4B Deal to Boost Heart Drug Pipeline - USA Herald
Buyout Of Tourmaline By Novartis Primarily On Pacibekitug IL-6 Novel Mode Of Action (TRML) - Seeking Alpha
Wild Moves In Stocks From Crypto Plans, Deal News, And A Name Drop - Finimize
Tourmaline Bio To Be Acquired By Novartis AG For $1.4 Billion - citybiz
Novartis to gain heart drug in $1.4B deal for Tourmaline Bio - BioPharma Dive
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
This Small Biotech Stock Is Surging Today. Here's Why. - Yahoo Finance
LifeSci Capital Downgrades Tourmaline Bio to Market Perform From Outperform, $48 Price Target - MarketScreener
Novartis (NVS) to Acquire Tourmaline Bio for $1.4 Billion - GuruFocus
Tourmaline Bio, QMMM Holdings, Teck Resources And Other Big Stocks Moving Higher On Tuesday - Benzinga
Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition - AOL.com
Guggenheim downgrades Tourmaline Bio stock rating to Neutral on Novartis deal - Investing.com Canada
Novartis to acquire Tourmaline Bio - The Pharma Letter
Novartis to acquire Tourmaline Bio for $1.4 billion - MLex
Why Novartis' $1.4 Billion Takeover Of Tourmaline Bio Just 'Makes Sense' - inkl
Guggenheim Downgrades Tourmaline Bio to Neutral From Buy, $48 Price Target - MarketScreener
Novartis to Acquire Tourmaline Bio for $1.4 Billion - Contract Pharma
Novartis acquires Tourmaline Bio in deal worth $1.4B - PharmaLive
Novartis expands in cardiovascular disease with $1.4bn Tourmaline Bio acquisition - MarketScreener
Novartis Secures $1.4 Billion Deal to Acquire Tourmaline Bio - Vocal
This Biopharma Stock Is Soaring 58%. Novartis Is Acquiring It. - MSN
Tourmaline Bio Stock Just Rocketed 58% Pre-Market – Here’s What Happened - Stocktwits
Wedbush Downgrades Tourmaline Bio to Neutral From Outperform Over Novartis Takeover, Price Target is $48 - MarketScreener
Novartis to spend $1.4B on Tourmaline Bio, gaining new heart drug - Endpoints News
Wall Street Breakfast Podcast: Nebius Rockets On $17B Microsoft Deal - Seeking Alpha
Tourmaline Bio surges 57% on Novartis merger deal - breakingthenews.net
Tourmaline Bio Merges with Novartis for $1.4 Billion - TipRanks
Tourmaline Bio to receive termination fee of $68.5 million if merger terminatedSEC filing - MarketScreener
Tourmaline Bio to Be Acquired by Novartis; $47.95M Termination Fee, Option Cashouts - Stock Titan
Novartis (NVS) to Acquire Tourmaline Bio in $1.4 Billion Deal - GuruFocus
Novartis acquista l’azienda di biotecnologia Usa Tourmaline Bio per 1,4 miliardi di dollari: premio d... - firstonline.info
TRML Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Tourmaline Bio, Inc. Is Fair to Shareholders - Business Wire
Novartis to Buy Tourmaline Bio for $48 Per Share in Cash - MSN
Novartis Agrees to Buy Tourmaline Bio for $48 Per Share in Cash - Bloomberg
Novartis to buy Tourmaline Bio for USD 1.4 billion - Medical Dialogues
Is now a turning point for Tourmaline Bio Inc.2025 Trading Volume Trends & Free Weekly Chart Analysis and Trade Guides - Newser
BREAKING NEWS: Novartis Buys Tourmaline Bio, Setting Up Showdown With Novo Nordisk - insights.citeline.com
Novartis strikes $1.4bn deal for Tourmaline Bio - Proactive financial news
Novartis to purchase US firm Tourmaline Bio for $1.4 billion - MSN
Tourmaline Bio To Be Acquired By Novartis; Was TRML Stock In Your Investment Portfolio? - RTTNews
Tourmaline Bio Agrees to $1.4 Billion Takeover by Novartis - MarketScreener
Novartis to acquire Tourmaline Bio in $1.4B all-cash deal - MSN
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) - Ariva
Tourmaline Bio Inc (TRML) 財務データ
収益
当期純利益
現金流量
EPS
1.96%
1.11%
大文字化:
|
ボリューム (24 時間):